# Vanda Pharmaceuticals Inc. (VNDA)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $359M  
**Price:** $6.08 (+0.91%)

> Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of therapies addressing high unmet medical needs in areas such as sleep-wake disorders, psychiatric and neurologic conditions, motion sickness, inflammatory skin diseases, and gastrointestinal or treatment-related nausea and vomiting. Its commercial portfolio includes HETLIOZ for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome, Fanapt for schizophrenia and bipolar I disorder, PONVORY for relapsing forms of multiple sclerosis, and NEREUS for preventing motion-induced vomiting. The company also advances a pipeline featuring imsidolimab for generalized pustular psoriasis, Bysanti, tradipitant for additional indications including GLP-1-induced nausea, and long-acting iloperidone formulations. Vanda Pharmaceuticals Inc. operates as a global player, selling products primarily in the United States with presence in Israel, Europe, and Canada, emphasizing rare disorders and conditions with limited treatment options. Founded in 2002 and headquartered in Washington, DC, it combines marketed medicines with late- and mid-stage clinical development to serve patients worldwide.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $216M | — | -$151M | -$220M | — |
| 2024 | $199M | — | -$41M | -$19M | — |
| 2023 | $193M | — | -$14M | $3M | — |
| 2022 | $254M | — | $6M | $6M | — |
| 2021 | $269M | — | $42M | $33M | — |
| 2020 | $248M | — | $27M | $23M | — |
| 2019 | $227M | — | $23M | $116M | — |
| 2018 | $193M | — | $22M | $25M | — |
| 2017 | $165M | — | -$17M | -$16M | — |
| 2016 | $146M | — | -$19M | -$18M | — |
| 2015 | $110M | — | -$40M | -$40M | — |
| 2014 | $50M | — | $20M | $20M | — |
| 2013 | $34M | — | -$21M | -$21M | — |
| 2012 | $33M | — | -$29M | -$29M | — |
| 2011 | $31M | — | -$11M | -$10M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $489M | $162M | $327M | $85M | — |
| 2024 | $656M | $118M | $539M | $102M | — |
| 2023 | $648M | $104M | $545M | $136M | — |
| 2022 | $634M | $107M | $527M | $135M | — |
| 2021 | $594M | $89M | $505M | $52M | — |
| 2020 | $533M | $80M | $453M | $61M | — |
| 2019 | $484M | $73M | $411M | $45M | — |
| 2018 | $332M | $57M | $275M | $61M | — |
| 2017 | $205M | $74M | $131M | $34M | — |
| 2016 | $210M | $79M | $131M | $40M | — |
| 2015 | $213M | $80M | $133M | $51M | — |
| 2014 | $172M | $11M | $161M | $61M | — |
| 2013 | $143M | $99M | $44M | $65M | — |
| 2012 | $135M | $126M | $10M | $89M | — |
| 2011 | $183M | $149M | $33M | $88M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$109M | $998,000 | -$110M |
| 2024 | -$16M | $490,000 | -$16M |
| 2023 | $13M | $383,000 | $12M |
| 2022 | $32M | $679,000 | $31M |
| 2021 | $64M | $552,000 | $64M |
| 2020 | $52M | $2M | $50M |
| 2019 | $46M | $1M | $45M |
| 2018 | $30M | $368,000 | $30M |
| 2017 | -$2M | $2M | -$4M |
| 2013 | -$40M | $176,000 | -$40M |
| 2012 | -$45M | $2M | -$47M |
| 2011 | -$28M | $275,000 | -$29M |
| 2010 | -$11M | — | — |
| 2009 | $169M | — | — |

Source: [CompaniesByCap](https://companiesbycap.com/company/VNDA)